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Immunization of  mice with syngeneic Moloney lymphoma cells  induces virus- 
neutralizing  antibodies.  The same sera also  react,  as a rule,  with the surface  of 
Moloney, Friend, and Rauscher virus-induced neoplastic  cells.  Operationally, 
the latter  type of reactivity is usually designated as anti-Friend-Moloney- 
Rauscher or anti-MCSA  I  (Moloney virus-induced  cell  surface  antigen)  antibody 
(1). Since the virally  induced lymphoma cells  continue to produce virus,  as a 
rule, it was difficult  to decide whether membrane-inserted virion  proteins or 
virally induced cellular  antigen(s) serve as the target of the latter  reaction. 
Under certain  conditions,  virus  neutralizing  activity  could be absorbed without 
affecting  anti-MCSA cytotoxicity,  supporting the hypothesis of  nonidentity (2). 
These experiments were performed using a Moloney lymphoma (YAC) and an 
L-cell subline (A9). Both cells  reacted with mouse sera immunized  against 
syngeneic Moloney lymphoma cells  but while absorption with L cells  removed 
both virus-neutralizing  activity  and reactivity  against L cells,  the reactivity 
against the YAC  cells  was not affected. YAC  cells  removed the reactivity 
against both. We concluded therefore  that at least  two antibody specificities 
were present, one reacting with the virus envelope, and another with the 
surface  of  the lymphoma cells.  L cells  carry the former antigen only,  whereas 
YAC cells  contain both. 
Monospecific antisera directed  against purified  C viral  proteins  were found 
to react against membrane-associated virion  proteins,  regularly expressed on 
the surface  of  virus-producing cells  (3-5).  The question of  whether any of  these 
could be identical  with MCSA  was approached by comparing sublines of the 
YAC lymphoma differing  in  their  MCSA  expression.  Immunoresistant sublines, 
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low or deficient in MCSA were derived by immunoselection, consisting of serial 
cytotoxic exposure to mouse antisera, combined with passage in preimmunized 
mice  (6). The original  and the  MCSA-deficient lines  reacted in  a  virtually 
identical fashion with a spectrum of antivirion protein sera, directed against 
gp71,  p30, p15, pl5(E),  p12, and  pl0  (7). This  suggested that  MCSA  was 
distinct from these virion proteins. 
We have recently obtained direct biochemical evidence showing that MCSA 
was distinct from H-2 and from the virion proteins gp71, p30, pl5(E), p12, and 
pl0 (8). 
The present paper deals with the question of  whether there is any relationship 
(including steric association) between MCSA  and viral envelope proteins on 
the cell surface, as judged by antibody-induced redistribution and capping. We 
have  also  approached the  same problem by reciprocal inhibition tests  with 
complete or disrupted virus or purified viral proteins compared to YAC and L 
cells. 
Materials and Methods 
Cells.  The YAC and YA7C lymphomas were induced by inoculating Moloney leukemia virus 
(MLV) to newborn A and (A × C57BI)FI mice, respectively  (9).  The characteristics  of  YAC cell- 
surface  antigens and virus  production have been described  in a series  of  publications  (6, 10, 11). 
Both tumors were maintained in  the ascites  form in syngeneic mice. 
The L-cell  subline used in the present experiments was a clonal derivative (clone 3C) of 
AgHT, a highly malignant A9 variant (12).  Like other L-cell  sublines,  A9HT produces a C-type 
virus  that shows a certain  resemblance to endogenous mouse viruses.  It is N-tropic (10,  11, 13) 
and lacks  leukemogenic activity  (14,  15).  In the XC test,  it  induces distinct  syncytia  rather than 
plaques (16).  The A9HT cells  were grown in Eagle's  Minimum Essential Medium with 5% fetal 
calf serum. 
Viruses.  Two  different  Rauscher  leukemia  virus  (RLV)  batches  and  one  MLV batch  was 
obtained through the Office of Resources and Logistics, Virus Cancer Program, National Cancer 
Institute,  Bethesda,  Md.  Batch  448  contained  concentrated  culture  fluid  from  RLV-infected 
JLS-V9 cells (RLV/JLS), purified through sucrose gradient centrifugation. The protein content 
was 3.93 mg/ml (17). 
The other batch (RLP-QQ) consisted of viremic plasma of RLV-inoculated BALB/c mice, and 
was designated RLV/BALB plasma. In the focus induction test on S  +  L  -  cells (18) it contained 
104.7 focus-inducing uniSs/ml.  MLV was concentrated and purified on sucrose gradient from the 
culture fluid of NIH 3T3 cells (batch 599-18-3,  designated MLV/NIH) to a  concentration of 1.16 
mg proteirdml. 
MLV  was  also  collected  from  roller  cultures  of  YAC  lymphoma  cells,  the  medium  was 
concentrated and banded in sucrose gradients (MLV/YAC). Protein concentration was 0.78 mg/ml. 
Antigens.  Purified  Friend virus  (FV),  gp71,  and pl5(E)  were  the generous  gift of Dr.  W. 
Schiller,  Max-Planck-Institut  fiir  Virueforschung,  Tiibingen,  Germany.  RLV  p12  was  kindly 
provided by Dr. J. R. Stephenson, National Cancer Institute. RLV p30 was obtained through the 
Office of Resources and Logistics, Virus Cancer Program, National Cancer Institute. 
Antisera.  Anti-H-2"  serum  was  produced  by  immunizing  ASW  mice  with  pooled  spleen, 
kidney,  and  liver suspensions from  A  mice,  inoculated subcutaneously  at  biweekly  intervals 
during 14-24 wk.  The mice were bled 7-10 days after the last injection. In the microcytotoxicity 
test, the serum was used at a  1:6,000 dilution against A lymph node cells (titer 1:24,000). 
Mouse antisera to YAC  (designated anti-ML sera) were produced in (A  x  C57B1)FI or (A  × 
C57L)F~  mice by three to six injections of 6,000 fads irradiated YA7C or YAC cells.  Sera were 
collected 1 wk after the last injection. 
The rabbit and goat anti-FVgp71 and rabbit anti-FVpl5(E) sera were the generous gift of Dr. 
W. Sch/ifer. The goat antisera to purified RLV proteins were kindly provided by Dr. B. Hampar, 
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Bronx, N.Y.;  (anti-p15 and anti-Groes p12) by Dr. J.  R.  Stephensen National Cancer Institute, 
Bethesda,  Md.  (anti-pl2).  None of the goat or rabbit antisera reacted with a  series of control 
mouse cells,  including normal A  lymphocytes and the cell lines, NIH/3T3,  BALB/3T3, and JLS- 
V9 (7). 
Cytotoxicity-Inhibition Assay.  A  microassay  (7)  was used in which 2  ftl of serial antiserum 
dilutions in balanced salt solution (BSS) with 1% gelatin (BSS/gel) were injected under paraffin 
oil  into  rings  of microtrays  (M~ller-Coats  A/S,  Moss,  Norway)  with  an  automatic  Hamilton 
syringe.  For  the  inhibition assay,  antigenic material  was  diluted  in  antiserum  at  the  final 
dilution which still gave 60-90% killing. 6 to 10 three-to fivefold dilution steps were tested in at 
least two repeat experiments.  108 target cells in 1 al were added to each droplet and the plates 
were  incubated for 20  rain  at  37°C.  Subsequently,  1  /~1 of rabbit complement was  added  at a 
dilution of 1:10  for  A9HT,  1:20  for  YAC,  and  1:40  for lymph node  cells.  Plates  were  further 
incubated for 45 min. Thereafter 0.5/~l trypan blue was added to each drop and the results were 
read microscopically. The ASW anti-A serum was tested against normal A lymph node cells. All 
other sera were tested against the YAC lymphoma. 
Membrane Immunofluorescence and Capping Experiments.  gpT1 and pl5(E) were detected on 
the cell membrane using a  1:15 diluted rabbit anti-FVgp71 and a  1:2 diluted rabbit anti-FVpl5(E) 
antisera,  followed by fluorescin isothiocyanate (FITC)-conjugated goat anti-rabbit Ig antibodies 
(Hyland  Laboratories,  Los  Angeles,  Calif.),  diluted  1:20.  MCSA  and  H-2  a  were  detected  by 
exposure  to  the  corresponding mouse antiserum,  diluted  h2,  followed by tetramethylrodamin 
isothiocyanate (TRITC)-conjugated goat anti-mouse Ig (Hyland Laboratories) diluted 1:4. 
Redistribution and capping were induced by incubating stained cells at 37°C.  Aliquote were 
taken  every  5  min,  fixed  with  glycerol:  BSS  1:1  and the  proportion of cap-positive  cells  was 
determined in relation to the total number of membrane fluorescence-positive cells.  Membrane 
fluorescence-positive cells with less than half of their circumference stained were registered as 
capped. 
For double staining and cocapping experiments, cells were exposed to the first antibody for 30 
min at 37°C to induce cap formation, and subsequently transferred to BSS/gel containing 10  -2 M 
sodium azide and chilled to 4°C to avoid further redistribution. Thereafter the cells were stained 
for  the  second  antigen  with  the  opposite  conjugate,  fixed,  and  examined  for  red  and  green 
fluorescence in a Leitz Ortholoux microscope (E. Leitz, Wetzlar, West Germany) with a Ploem-type 
"Opakilluminator" system as described (19). For FITC fluorescence, 470 nm blue excitation light 
was  used,  with  4  mm  BG38  +  1.5  mm  BG12  +  AIA70  (Schott,  Mainz,  West  Germany)  as 
primary filters, 495 nm interference plate and K510 barrier filter.  For TRITC fluorescence, 546 
nm green excitation light was  used,  with  a  4-mm  BG38  +  2  mm  BG36  +  AL546  as  primary 
filters,  580 nm interference plate,  and K590  barrier filter.  Single cells were  photographed  for 
green and red fluorescence differentially while the field between the exposures was shifted to 
observe the distribution pattern of both antigens. 
Results 
Expression of Viral Structural Proteins  on  YAC  and A9HT  Cells.  YAC 
and A9HT cells were tested for their cytotoxic sensitivity to antisera directed 
against  purified viral  components  (Table  I).  Both  cell lines  reacted  with  all 
sera.  With  the  exception  of anti-FVpl5(E)  and  anti-Gross  p12,  AgHT  cells 
reacted more weakly than did YAC cells with the antivirion protein reagents. 
Also, in accordance with previous results (2),  A9HT cells reacted more weakly 
with the mouse anti-ML serum. 
Analysis of the Mouse Anti-ML Serum by Inhibition Tests 
INHIBITION WITH VIRUS.  Four different preparations were used;  two RLV 
and two MLV.  As  expected,  the  cytotoxicity of goat  anti-FVgp71  serum  was 
inhibited completely by all four virus preparations  (Table II and Fig.  1, upper 
part),  although at varying efficiency, 0.73 ng RLV/JLS, 4.0 ng MLV/NIH,  and 1524  DISTINCT  ANTIBODIES  TO  MOLONEY  CELL  SURFACE  ANTIGEN 
TABLE  l 
Expression of Viral Structural Proteins on YAC and A9HT 
Cells 
Antiserum 
Target  cells 
YAC  A9HT 
Goat anti-FVgp71  8,700*  2,900 
Goat anti-RLVp30  25  10 
Rabbit  anti-FVp15(E)  17  27 
Goat anti-RLVp15  40  <I05 
Goat anti-Grossp12  <105  35 
Goat auti-RLVp12  25  10 
Mouse anti-ML  250  62 
*  Reciprocal of antiserum  dilution  which  gave  0.5  cytotoxic  index. 
$  Cytotoxic index 0.40 at 1:10 dilution of antiserum. 
TABLE II 
Inhibition of Cytotoxic  Activity with Various Virus Preparations 
Antiserum*  Target 
cell 
Mouse anti-ML  YAC 
Coat anti-FVgp71  YAC 
Coat anti.RLVp30  YAC 
ASW anti-A  Alv~l 
* Dilution:  anti-ML,  1:160 
RLV/JLS 
Dis- 
Inhibition  Intact$  rupted 
ng 
None  ->2,120 ] ->2,120 
Complete  0.9  1.8 
Complete  15.3  0.8 
None  _>2,120 
RLV/BALB 
plasma 
Inhibition  FIU§ 
30%  31.3 
Complete  7.8 
Complete  3.9 
None  ->31.3 
MLV/NIH 
Dis- 
Inhibition  Intact  rupted 
ng 
30%  2,090  ~  2,000 
Complete  .5  181 
Complete  725  I  74.2 
None  ->2,000 I 
anti-FVgp71, 1:5,000;  anti-RLVp30,  i:i0;  anti-A, 1:6,000. 
MLV/YAC 
Dis- 
Inhibition Intact rupted 
ag 
None  ->980  ->980 
Complete  780  780 
Complete  200  61.2 
None  ->980 
$ Figures correspond  to the maximum amount of protein  tested in cases  where there was no or only partial  inhibition,  or the minimum 
amount which gave complete (100%) inhibition. 
§ FIU, focus-inducing  units on S+L  - cells. 
II A lymph node cells. 
123.0  ng  MLV/YAC  was  needed  for  50%  inhibition.  The  goat  anti-RLVp30 
antiserum  was  also  inhibited  completely.  None  of  the  virus  preparations 
inhibited  anti-H-2 a  cytotoxicity.  With  the  mouse  anti-ML  serum,  different 
results were obtained,  depending on the target cell. RLV/JLS and MLV/YAC 
did not  inhibit  cytotoxicity  against  YAC  cells while RLV/BALB  plasma  and 
MLV/NIH were partially inhibitory in doses above 1 ~g. All virus preparations 
inhibited cytotoxicity  against  AgHT cells  (Fig.  1,  lower part)  This  is  in line 
with our previous finding that the mouse antiserum reacts with viral envelope 
antigen on A9 cells while YAC cells have additional antigens, not expressed on 
the viral envelope. 
INHIBITION  WITH  PURIFIED  VIRAL  PROTEINS  FVgp71,  RLVp30,  FVplS(E),  AND 
RLVpl2.  Further  evidence  was  obtained  to  confirm that  the  mouse  anti-ML 
serum reacted with viral envelope components on A9HT cells when we found 
that purified FVgp71  inhibits cytotoxicity completely (Fig.  2).  No such inhibi- 
tion was obtained with YAC target cells (Fig.  2 and Table III). 
None  of the three  virion proteins  RLVp30,  FVp15(E),  and  RLVp12  showed 
any inhibition of the mouse anti-ML serum against YAC.  The anti-FVp15(E), 
anti-RLVp15,  and  anti-Gross  p12  antisera  were  completely  inhibited  by E.  M.  FENYO,  E. 
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FIG. 1.  Inhibition  of the cytotoxic  activity of goat anti-FVgp71 (upper) and mouse anti- 
ML (lower) sera by MLV/NIH  virus. Target cells: YAC O and A9HT A. 
FVpl5(E) antigen (Table III), indicating that all three detect the same antigen. 
INHIBITION  TESTS  WITH  DISRUPTED  VIRUS.  Three virus preparations were 
disrupted by 10 cycles of freeze-thawing. Increase of the p30 activity was taken 
as the measure of disruption, assayed by the inhibition of the anti-p30 serum. 
For RLV/JLS 30-fold increase, for MLV/NIH 10-fold,  and for MLV/YAC 3-fold 
increase was obtained (Fig. 3). The increase seems to relate to the state of the 
virus preparation before treatment. For example, untreated RLV/JLS contained 
less p30  than gp71  and showed the largest increase of p30  activity among the 
virus preparations tested. MLV/YAC contained more p30 than gp71 and freeze- 
thawing led to a threefold increase only. 
Disrupted virus particles still failed to inhibit the cytotoxicity of  the anti-ML 
serum  against  YAC  cells  (Fig.  3).  This  argues  against the  possibility that 
MCSA is located within the virus particle. 
Membrane Immunofluorescence  Reactivity of YAC Cells 
KINETICS OF  CAP  FORMATION.  Fig.  4 shows the frequency of capped YAC 
cells as a function of time aiter exposure to four antisera. A high proportion of 1526  DISTINCT  ANTIBODIES  TO  MOLONEY  CELL  SURFACE  ANTIGEN 
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FIG. 2.  Inhibition  of the cytotoxic  activity  of the goat anti-FVgp71 (upper) and mouse 
anti-ML (lower)  serum by purified  viral  proteins.  Target cells:  YAC  © and A9HT ix. 
TABLE III 
Cross-Inhibition of Antisera with Virion Proteins 
Antiserum* 
FVgp71  RLVp30  FVplS(E)  RLVpl2 
Inhibition  ng$  Inhibition  ng  Inhibition  ng  Inhibition  ng 
Mouse anti-ML  10-30%  890-3,600  None  ->360  None  ->2,800  None  ->80 
Goat anti.FVgp71  Complete  1  None  _>360  None  ->2,800  None  ->80 
Goat anti-RLVp30  None  ->3,600  Complete  28  None  ~_2,800  None  ->80 
Rabbit anti-FVplS(E)  None  -> 3,600  None  ->360  Complete  350  None  ->80 
Goat anti-RLVp15  Complete  500 
Goat anti-Grossp12  Complete  175 
Goat anti-RLVp12  None  ->3,600  None  ->360  None  ->2,800  Complete  40 
* Dilution: anti-ML 1:160 (anti-YAC),  1:10 (anti-YA7C);  anti-FVgp71 1:5,000; all others 1:10. Target cell: YAC. 
t  Figures denote the maximum amount of protein tested in cases  of partial or no inhibition, or the minimum amount which gave 
complete (100%) inhibition, 
the cells capped after exposure to anti-FVgp71,  anti-FVpl5(E), and anti-H-2  a 
sera,  (66,  53,  and 59% respectively), plateauing after 25-30 rain at 37°C.  The 
caps  were restricted to  one pole  of the  cell and  appeared as  one continuous 
brilliant spot of fluorescence. In contrast,  only about 15% of the cells capped 
with anti-ML serum after 30 min incubation. The pattern was also different, E.  M.  FENYO,  E. 
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FIG.  3.  Inhibition  of the  cytotoxicity of goat  anti-RLVp30  (upper)  and  mouse  anti-ML 
(lower) serum by whole (  ) and freeze-thawed ( ..... ) MLV/NIH  virus. Target: YAC cells. 
redistribution  rather  than  capping,  with  numerous  small  spots  and  dots, 
appearing over one-half of the cell circumference  (Fig. 5). This is in agreement 
with  our  previous  observation  (20)  showing  a  very  poor  MCSA  capping, 
compared to that of H-2. It is of interest that the capping of the virion proteins 
resembles  the  pattern  of  H-2  and  differs  clearly  from  the  redistribution  of 
MCSA. 
DOUBLE STAINING AND  COCAPPING.  These experiments were  carried out to 
see if the different antigens represent distinct molecular entities on the surface 
of  YAC  cells  and  whether  or  not  their  antibody-induced  redistribution  is 
independent.  YAC cells were stained for gp71,  allowed to cap, and transferred 
to sodium azide-containing medium at 4°C. Subsequently, the cells were stained 
for MCSA.  Capping of gp71 did not affect the distribution of MCSA,  as shown 
by the double-staining procedure.  Fig.  6 shows complete gp71 capping (green) 
with virtually continuous MCSA ring fluorescence. 
Redistribution of gp71  (green) followed by staining for H-2  a (red)  showed no 
cocapping of H-2  a (Fig. 7). Fig. 8 shows capping of pl5(E) on YAC cells with no 
subsequent  cocapping  of  MCSA  (Fig.  8).  These  experiments  confirm  that 
MCSA is distinct from gp71 and pl5(E). 1528  DISTINCT  ANTIBODIES  TO  MOLONEY  CELL  SURFACE  ANTIGEN 
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F1o. 4.  Capping of MCSA  ©, H-2  a Lk, gp71 [], and pl5(E) V  on YAC  cells.  Cells  were 
incubated with the various antisera at 4°C for 30 rain,  washed, and reacted with the 
appropriate anti-immunoglobulin conjugate for 30 rain at 4°C. The stained cells  were 
incubated at 37°C and samples were removed for  estimating the frequency of  capped cells 
at  the indicated  times. Closed symbols represent control  cells  incubated at 4°C for  30 rain. 
Mouse anti-ML sera  neutralize  MLV  (I,  2),  presumably due to  their  reactivity 
against gp71 (21,  22).  To assess this  reactivity,  YAC  cells  were first  incubated 
with mouse anti-ML serum at 37°C for  I h. They were subsequently transferred 
to sodium azide-containing medium  at 4°C, and stained for either gp71 or 
p15(E). Finally,  the cells  were stained with the red anti-mouse conjugate and 
fixed. As shown in Fig. 9 and 10, the anti-MLV serum induced redistribution 
and capping of gp71. This was visualized by creating a sandwich with the 
green anti-gp71 reagent at conditions which did not  allow capping of  the latter. 
Since the maximum  frequency of  cells  with MCSA  caps was always low (Fig. 
4), most of  the cells  that capped gp71 did not redistribute  their MCSA.  When 
stained with the red conjugate, the latter  appeared as a complete ring. Fig. 5 
shows that a  similar procedure did not affect p15(E). The  latter antigen 
remained dispersed over the total  cell  circumference and neither redistributed 
nor capped after  exposure to the anti-ML antiserum, not even on the few cells 
that capped their  MCSA.  Incubation of YAC  cells  for 1 h at 37°C in BSS/gel 
before staining for gp71 or p15(E) at 4°C showed a diffuse  distribution of  the 
antigens, confirming that incubation at 37°C does not induce redistribution  by 
itself. 
This procedure has thus confirmed that  the mouse anti-ML serum also  reacts 
with  gp71.  However,  when  assayed by membrane  immunofluorescence  or 
cytotoxicity  against  YAC cells,  the  anti-gp71 reactivity  is  usually  overshadowed 
by the MCSA  reaction. E.  M.  FENYO,  E.  YEFENOF,  E.  KLEIN,  AND  G.  KLEIN  1529 
Fro.  5.  Pre-incubation of YAC with anti-ML antiserum does not induce capping of plSE. 
Cells were incubated with anti-ML for I h at 37°C, transferred to a sodium aside-containing 
medium  at  4°C,  and  stained  for  p15  (green),  and  with  anti-mouse  immunoglobulin 
conjugate (red). MCSA is redistributed into several spots and dots, spread over one half of 
the cell circumference. Magnification is 540 times. 
FIG.  6.  Capping of gp71  (green) does not induce cocapping of MCSA (red). YAC-IR cells 
were  stained  for  gp71  and  incubated  at  37°C  for  30  min.  Subsequently,  they  were 
transferred to sodium azide-containing medium at 4°C and stained for MCSA.  Magnifica- 
tion is 540 times. 
FIG.  7.  Capping  of gp71  (green) does not induce cocapping of H-2  a  (red).  YAC-IR cells 
were  stained  for  gp71  as  in  Fig.  6  and  then  transferred to  a  sodium  azide-containing 
medium at 4°C  and stained for H-2  a. Magnification is 540 times. 
FIo.  8.  Capping of p15 (green) does not induce cocapping of MCSA (red). YAC cells were 
stained for plSE and incubated 30 rain at 37°C.  Subsequently, they were transferred to a 
sodium azide-containing medium at 4°C and stained for MCSA. Magnification is 540 times. 
Fro.  9.  Pre-incubation of YAC  cells with  anti-ML  antiserum  induces capping  of gp71 
(green), while MCSA remains distributed (red).  Cells were treated as in Fig.  5, but gp71 
was visualized instead of pl5E.  Magnification is 700 times. 
FIo.  10.  Same  as  Fig.  6  but  gp71  is  redistributed into  aggregates  which  precede  cap 
formation.  Magnification is 700 times. 
Discussion 
MCSA could first be distinguished from virion protein antigens in immuno- 
resistant (IR) lines of the YAC Moloney lymphoma. The IR lines were derived 
by repeated immunoselection, alternating between in vitro cytotoxic treatment 1530  DISTINCT  ANTIBODIES  TO  MOLONEY  CELL  SURFACE  ANTIGEN 
with  anti-ML sera  in  the  presence  of  complement,  and  passage  through 
preimmunized mice.  They are  resistant to mouse anti-ML sera,  while their 
sensitivity  to the cytotoxic effect of antisera agm'nst gp71,  p30, p15, p15(E),  p12, 
and  pl0  virion antigens is  unchanged (7). NP40  solubilization of YAC  cells 
allowed the physical separation of MCSA from the virion proteins and from H- 
2  (8). In a  similar  manner  to  H-2  a  and  gp71,  solubilized  MCSA  bound  to 
concanavalin-A columns and could be eluted with a-methyl-mannoside. The 
eluted material could be separated by further fractionation on Sephadex G-200 
into distinct MCSA, gp71,  and H-2 peaks. MCSA was identified by inhibition of 
cytotoxicity of the  mouse  anti-ML serum  against  YAC  lymphoma cells.  It 
appeared as an approximately 110,000 mol wt species. 
The present study reaffirms the conclusion that MCSA is an entity, distinct 
from  surface-associated virion  proteins.  While  H-2  and  the  virion  proteins 
underwent rapid, high-frequency redistribution and capping, on ligand contact, 
MCSA  showed only a  very limited redistribution and  virtually no  capping. 
Furthermore, MCSA did not cocap with the virion proteins gp71 or pl5(E). H-2 
did  not  cocap  with  any  of the  virion  proteins  either;  results  which  are  at 
variance with those of Schrader et al.  (23). 
Mouse anti-ML sera contain virus-neutralizing activity (1,  2),  attributed to 
antibodies against gp71  (21,  22). Our cytotoxicity and fluorescence tests con- 
firmed that the anti-ML serum reacts with at least two different sites on the 
surface of  the YAC cell, identified as gp71 and MCSA, respectively. The serum 
could induce the redistribution and capping of surface-associated gp71  mole- 
cules, confirmed by a  subsequent second labeling with heterologous monospe- 
cific anti-gp71 serum.  Under ordinary test conditions, the stronger and much 
less  cappable  anti-MCSA reaction  predominates,  and .gp71 capping remains 
masked. Since gp71  was clearly capped by the mouse serum, this experiment 
also shows that the lack of MCSA capping cannot be ascribed to the serum 
source and must be therefore due to a relatively firmer membrane anchorage of 
the antigen. 
Cytotoxicity by  the  anti-ML  serum  against  YAC  target  cells  was  only 
partially inhibited or not at all inhibited by purified gp71  (or virus). This is in 
line  with  the  fact that  YAC  cells  carry both  gp71  and  MCSA.  A9HT  cells 
express gp71 but lack MCSA (2). As expected, their reaction with the anti-ML 
serum could be completely inhibited by gp71  (or by virus). 
Our findings that the mouse anti-ML sera contain antibodies against both 
virion  (anti-gp71)  and  nonvirion  cell-surface  components  (anti-MCSA)  on  a 
Moloney virus-induced lymphoma cell are at variance with those of Friedman 
et al.  (24) on the Friend system. They found that the cytotoxic effect of mouse 
antisera against FV-infected spleen cells could be completely inhibited by FV. 
Similar findings were reported by Hogg (25) using sera of MSV regressor mice 
and an established culture line of a  Moloney sarcoma as target cells. 
The mouse anti-ML serum did not contain antibodies to pl5(E),  p30,  or p12 
at a level detectable by the methods used; cytotoxicity and membrane immuno- 
fluorescence.  In  addition,  the  membrane  redistribution  of pl5(E)  was  not 
influenced by the mouse anti-ML serum, unlike gp71 which was capped. 
Several experimental findings emphasize the in vivo importance of MCSA. 
First, there was a  close parallelism between in vivo rejectability and in vitro E.  M.  FENYO,  E. YEFENOF,  E. KLEIN,  AND  G. KLEIN  1531 
MCSA expression when a large number of Moloney lymphomas were compared 
(9).  Second, in a  group of backcross mice segregating for low and high anti- 
MCSA  reactivity,  only  those  with  antibodies  to  MCSA  showed  protection 
against lymphoma transplants (26). On the contrary, the presence of anti-viral 
antibodies did not show any correlation to the ability of tumor rejection. Third, 
immunoselection of YAC invariably results in sublines with decreased MCSA 
content (6) but leaves viral protein antigens unchanged (7). 
Summary 
Immunization of mice with heavily irradiated syngeneic Moloney lymphoma 
cells evokes antibodies against the major viral envelope antigen, gp71,  and the 
Moloney virus-induced cell  surface  antigen  (MCSA).  A9HT  cells,  an  L-cell 
subline, react with the antibodies against the viral envelope antigen only; this 
reaction can be  completely inhibited by virus or purified gp71.  Reactivity to 
Moloney lymphoma cells (YAC) was only partially inhibited (maximum 30%) 
or  not  at  all.  This  can  be  attributed to  the  reaction of the  YAC  cells  with 
antibodies directed against MCSA, a nonvirion cell surface component accord- 
ing to both biological and biochemical evidence. 
Antibody-induced capping of gp71  or plS(E)  did not change the membrane 
distribution of MCSA or H-2, indicating that these antigens represent distinct 
entities on the cell surface. MCSA showed only minimal capping and thereby 
differed in behavior from both H-2  and virion antigens, gp71  could be capped 
by the mouse antiserum as revealed by subsequent staining with monospecific 
anti-gp71 antiserum. Under ordinary test conditions this reactivity is oversha- 
dowed by the reaction against MCSA.  The lack of MCSA capping reflects a 
difference in anchorage of this antigen. 
Purified viral proteins and  antisera  against them were the generous giR of Dr.  B.  Hampar, 
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College of Medicine of Yeshiva University, Bronx, N. Y.  (anti-RLVpl5 and anti-Grosspl2) and 
Dr. W. Sch~fer,  Max-Planck-Institut fiir  Virusforschung, Tiibingen,  Germany  (anti-FVgp71, 
anti-FVp15(E), FVgp71 and FVp15(E) antigens).  We thank Dr. W. Siegert  for his advice in 
purification of MLV/YAC  virus. The expert technical  assistance of Miss Irma Jansson  is 
gratefully  acknowledged. 
Received for publication 23 June 1977. 
References 
1.  Klein, E., and G. Klein. 1964. Mouse antibody production test for the assay of the 
Moloney virus. Nature (Lond.).  204:339. 
2.  Feny6, E. M., G. Grundner, and E. Klein. 1974. Virus associated antigens on L cells 
and Moloney lymphoma cells. J. Natl. Cancer Inst. 52:743. 
3.  Ikeda, H., T. Pincus,  T. Yoshiki, M. Strand, J. T. August, E. A. Boyse, and R. C. 
Mellors. 1974. Biological expression of antigenic determinants of murine leukemia 
virus proteins gp69/71 and p30. J. Virol.  14:1274. 
4.  Hunsmann,  G.,  M.  Claviez,  V.  Moennig,  H.  Schwarz,  and  W.  Sch~fer.  1976. 
Properties of mouse leukemia viruses.  X. Occurrence of viral structural antigens on 
the cell surface as revealed by a cytotoxicity test. Virology.  69:157. 
5.  Schwarz, H., G. Hunsmann, V. Moennig, and W. Sch~fer. 1976. Properties of mouse 1532  DISTINCT  ANTIBODIES  TO  MOLONEY  CELL  SURFACE  ANTIGEN 
leukemia  viruses.  XI.  Immunoelectron  microscopic  studies  on  viral  structural 
antigens on the cell surface. Virology.  69:169. 
6.  FenyS, E. M., E. Klein, G. Klein, and K. Swiech. 1968. Selection of an immunoresis- 
tant  Moloney  lymphoma  subline  with  decreased  concentration  of tumor-specific 
surface antigens. J. Natl. Cancer Inst. 40:69. 
7.  Feny6,  E.  M.,  and  G.  Klein.  1976. Independence  of Moloney  virus-induced  cell- 
surface antigen and membrane-associated virion antigens in immunoselected lym- 
phoma sublines. Nature (Lond.).  260:355. 
8.  Siegert, W., E. M.  FenyS, and G. Klein. 1977. Separation of the Moloney leukemia 
virus-determined cell surface antigen (MCSA) from known virion proteins associated 
with the cell membrane. Int. J. Cancer. 20:75. 
9.  Klein,  G., E.  Klein,  and G. Haughton.  1966. Variation of antigenic characteristics 
between different mouse lymphomas induced by the Moloney virus. J. Natl. Cancer 
Inst. 36:607. 
10.  FenyS, E.  M.,  K.  Nazerian,  and E.  Klein.  1974. Characteristics of routine  C-type 
viruses. II. The behavior of viruses resident in various cell lines and their hybrids 
on BALB/3T3 and mouse embryo fibroblast cultures. Virology.  59:574. 
11.  FenyS, E.  M., and G. Grundner.  1973. Characteristics of murine C-type viruses. I. 
Independent assortment of infectivity in one in vivo and four in vitro assays. Int. J. 
Cancer.  12:452. 
12.  Littlefield, J. W.  1964. Three degrees of guanylic acid-inosinic acid pyrophosphoryl- 
ase deficiency in mouse fibroblasts. Nature (Lond.).  203:1142. 
13.  Botis, S.,  M.  Janowski, and J.  R.  Maisin.  1976. L cell virus: Infectivity for type N 
and B mouse embryo cells. J.  Virol.  20:690. 
14.  Dales,  S.,  and  A.  F.  Howatson.  1961. Virus-like  particles  in  association  with  L- 
strain cells. Cancer Res. 21:193. 
15.  Kindig, D. A., and W.  H. Kirsten.  1967. Virus-like particles on established murine 
cell lines: electron microscopic observations. Science (Wash. D. C.).  155:1543. 
16.  FenyS, E. M., G. Grundner, F. Wiener, E. Klein, G. Klein, and H. Harris. 1973. The 
influence of the partner cell on the production of L virus and the expression of viral 
surface antigen in hybrid cells. J. Exp. Med.  137:1240. 
17.  Lowry,  O.  H.,  N.  J.  Rosenbrough,  A.  L.  Farr,  and  R.  J.  Randall.  1951. Protein 
measurement with the folin phenol reagent. J. Biol. Chem.  193:265. 
18.  Bassin,  R.  H.,  N.  Tuttle,  and  P.  J.  Fischinger.  1971. Rapid  cell  culture  assay 
technique for murine leukemia viruses. Nature (Lond.).  229:564. 
19.  Yefenof, E., G. Klein, M. Jondal,  and M.  B. A. Oldstone.  1976. Surface markers of 
human  B- and  T-lymphocytes. IX.  Two-color immunofluorescence studies  on the 
association  between  EBV  receptors  and  complement receptors  on the  surface  of 
lymphoid cell lines. Int. J. Cancer.  17:693. 
20.  Yefenof,  E.,  and  G.  Klein.  1974. Antibody-induced  redistribution  of normal  and 
tumor-associated surface antigens. Exp. Cell Res. 88:217. 
21.  Steeves, R. A., M. Strand, and J. T. August. 1974. Structural proteins of mammalian 
oncogenic RNA viruses: murine leukemia virus neutralization by antisera prepared 
against purified envelope glycoprotein. J. Virol.  14:187. 
22.  Fischinger, P. J., W.  Sch~fer, and D. P. Bolognesi. 1976. Neutralization of homolo- 
gous  and  heterologous  oncorna  viruses by antisera  against  the  p15(E)  and  gp71 
polypeptides of Friend murine leukemia virus. Virology.  71:169. 
23.  Schrader,  J.  W.,  B.  A.  Cunningham,  and  G.  M.  Edelman.  1975. Functional 
interactions of viral and histocompatibility antigens  at tumor cell surfaces. Proc. 
Natl. Acad. Sci.  U. S. A. 72:5066. 
24.  Friedman, M., F. Lilly, and S. G. Nathenson.  1974. Cell surface antigen induced by E.  M.  FENYO,  E.  YEFENOF,  E.  KLEIN,  AND  G.  KLEIN  1533 
Friend murine leukemia virus is also in the virion. J. Virol.  14:1126. 
25.  Hogg,  N.  M.  1976. Specificity of serum from rodents  immune to  Moloney C-type 
virus-induced tumors. Int. J. Cancer.  18:439. 
26.  ~mjS, B.,  R.  Kiessling,  G.  Klein,  and  S.  Povey.  Genetic  variation  in  antibody 
response  and  natural  killer  (NK)  cell  activity  against  a  Moloney  virus-induced 
lymphoma (YAC). Eur. d. Immunol.  In press. 